.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Moodys
McKinsey
QuintilesIMS
UBS
Julphar
Novartis
Express Scripts
Citi
Medtronic

Generated: July 28, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,062,667 protect, and when does it expire?


Patent ► Subscribe protects QUILLIVANT XR, DYANAVEL XR, KARBINAL ER, and TUZISTRA XR, and is included in four NDAs. There has been one Paragraph IV challenge on Quillivant XR.

This patent has nineteen patent family members in fourteen countries.

Summary for Patent: ► Subscribe

Title:Modified release formulations containing drug-ion exchange resin complexes
Abstract: A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.
Inventor(s): Mehta; Ketan (Cranbury, NJ), Tu; Yu-Hsing (West Windsor, NJ)
Assignee: Tris Pharma, Inc. (Monmouth Junction, NJ)
Application Number:11/724,966
Patent Claim Types:
see list of patent claims
Composition; Process; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Nextwave Pharms
QUILLIVANT XR
methylphenidate hydrochloride
FOR SUSPENSION, EXTENDED RELEASE;ORAL202100-001Sep 27, 2012RXYesYes► Subscribe► SubscribeY
Tris Pharma Inc
DYANAVEL XR
amphetamine
SUSPENSION, EXTENDED RELEASE;ORAL208147-001Oct 19, 2015RXYesYes► Subscribe► SubscribeY
Tris Pharma Inc
KARBINAL ER
carbinoxamine maleate
SUSPENSION, EXTENDED RELEASE;ORAL022556-001Mar 28, 2013RXYesYes► Subscribe► SubscribeY
Vernalis R And D Ltd
TUZISTRA XR
chlorpheniramine polistirex; codeine polistirex
SUSPENSION, EXTENDED RELEASE;ORAL207768-001Apr 30, 2015RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,790,700Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,202,537Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,491,935Modified release formulations containing drug-ion exchange resin complexes► Subscribe
9,522,191Modified release formulations containing drug--ion exchange resin complexes► Subscribe
8,747,902Modified release formulations containing drug-ion exchange resin complexes► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan200812649► Subscribe
Russian Federation2435569► Subscribe
Russian Federation2008140944► Subscribe
South Korea101495146► Subscribe
South Korea20080108520► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Mallinckrodt
Teva
Moodys
Federal Trade Commission
Dow
Johnson and Johnson
Colorcon
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot